SNRIs inhibit the reuptake of both serotonin and norepinephrine in the brain, thus increasing their levels in the synaptic cleft. This dual action can offer benefits over selective serotonin reuptake inhibitors (SSRIs), particularly for patients who do not respond adequately to SSRIs alone.
